Login to Your Account

Amyloid-Beta a Failed Hypothesis in Alzheimer's?

Signum, GSK Agree to Probe Phosphatase 2A as AD Target

By Marie Powers
Staff Writer

Friday, November 11, 2011
Privately held biotech Signum Biosciences Inc. signaled its intention to play in a bigger sandbox on Wednesday by signing an agreement with GlaxoSmithKline (China) R&D Co. Ltd. to advance Signum's phosphatase screening technology, which targets the phosphoprotein phosphatase 2A (PP2A) as a key mechanism in Alzheimer's disease (AD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription